Study Design: Systematic review.
Introduction
Degenerative disease of the cervical spine is the most common indication for cervical spine surgery.
1,2 Neurological consequences of such disease include radiculopathy and myelopathy, which result in progressive pain, disability, and diminished quality of life. The utility of nonoperative therapy for patients with degenerative cervical myelopathy (DCM) was previously investigated by Rhee et al 
Materials and Methods

Electronic Literature Search
A systematic review of the literature was conducted to identify relevant articles published up to May 18, 2015 . Electronic databases (PubMed, EMBASE, Cochrane Collaboration library) and reference lists of key articles were searched to identify prospective studies on adult patients with DCM (cervical spondylotic myelopathy or ossification of the posterior longitudinal ligament [OPLL] ) that evaluated outcomes or safety of operative treatment. For Key Question 1, we included studies that assessed functional, disability, and quality of life outcomes following surgical intervention. For Key Question 2, we identified studies that evaluated the impact of preoperative disease severity and duration of symptoms on postoperative outcomes. For Key Question 3, we searched for studies that summarized complications associated with surgery. Table 1 displays the PICO table and highlights the inclusion and exclusion criteria for this review. Studies were excluded if fewer than 50 patients were included, the follow-up was less than 1 year, arthroplasty procedures were performed, and the outcome metrics did not include modified Japanese Orthopaedic Association (mJOA), Neck Disability Index (NDI), or Nurick scores. For studies comparing operative and nonoperative outcomes, we only extracted data from the surgical arm. For studies that compared different types of surgery (eg, anterior vs posterior), we combined the results from both approaches. Studies that did not report primary outcomes but did analyze complications were included for Key Question 3. Two investigators (EDB, JRD) reviewed the full texts of potential articles to obtain a final collection of studies.
Data Extraction
We extracted the following data from the included articles: study design, patient demographics, diagnosis, surgical approach, preoperative and postoperative neurological status (mJOA, NDI, Nurick, Visual Analog Scale [VAS] scores), and complications. Preoperative disease severity and duration of symptoms were recorded when available. Each citation was independently reviewed by 2 of the authors.
Study Quality and Overall Strength of Body of Literature
The risk of bias was appraised by 2 of the study authors using the modified Newcastle-Ottawa Scale. 9 The evaluation for risk of bias is included in the supplemental material (available in the online version of the article).
Next, the overall quality of evidence with respect to each outcome was determined based on methodology outlined by the Grades of Recommendation Assessment, Development and Evaluation (GRADE) Working Group 10, 11 and recommendations from the Agency for Healthcare Research and Quality. 12, 13 The overall body of evidence is considered "Low" if all studies are observational. The quality of the body of evidence may be upgraded or downgraded depending on a number of factors. Criteria for downgrading 1 or 2 levels include (1) inconsistency of results, (2) indirectness of evidence, or (3) imprecision of the effect estimates (eg, wide variance). Alternately, the body of evidence may be upgraded 1 or 2 levels based on (1) large magnitude of effect or (2) doseresponse gradient.
A quality level of "High" indicates high confidence that the true effect lies close to the estimate of effect. A "Moderate" quality level reflects moderate confidence in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. A "Low" quality level represents limited confidence in the effect estimate; the true effect may be substantially different from the estimate of the effect.
11 "Very Low" ratings indicate very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. This rating may be used if there is no evidence or if it is not possible to estimate an effect.
Data Analysis
Outcomes were stratified by follow-up timing as short term (less than 12 months), medium term (13-36 months), and long term (>36 months). Effect measures were first defined as mean differences (MD) with missing standard deviations imputed using the highest value from included studies. Standardized mean differences (SMDs) were computed to reflect the heterogeneity of outcome measures for JOA and mJOA scores that are correlated but not identical.
14 Using Cohen's criteria, 15 an SMD of 0.2 to 0.49 represents a "small" effect, 0.5 to 0.79 a "moderate" effect, and 0.8 or greater a "large" effect. When it was necessary to merge multiple surgical cohorts from a single article, the weighted average scores were calculated and Cohen's approximation 16 for combining standard deviations was used. Results were further stratified by study quality based on risk of bias (high or low) to determine if there were qualitative and quantitative differences.
Results
Study Selection
The search strategy yielded 385 relevant citations, of which 312 were excluded based on their title and/or abstract. Seventy-seven studies were selected for full-text review. Forty-five of these were excluded for the following reasons: retrospective study design, sample included both radiculopathy and myelopathy, desired outcomes or preoperative and postoperative comparisons were not available, fewer than 50 patients, duplicated results from a separate study, or follow-up period less than 1 year. An overview of our selection process is summarized in Figure 1 . Thirty-two studies ultimately met the inclusion criteria and are summarized in this review. Study characteristics are provided in Table 2 ; sample sizes ranged from 52 to 479 patients, mean ages ranged from 46 to 65 years For studies that only provided demographic data stratified by treatment or other comparison groups, weighted means were calculated to provide an estimate for the entire study population.
c Same study population (multicenter AOSpine North American Study): Fehlings (2012) was included for perioperative and delayed complications; Fehlings (2013) included primary outcome results and provided data regarding the association of preoperative disease severity on change in impairment; Karpova (2013) analyzed data from a single center and provided data regarding the impact of preoperative symptom duration on change in impairment; and Tetreault (2013) provided supplemental modeling data using preoperative disease severity and symptom duration as predictors of achieving a mJOA 16. d This was a comparative study using a historical control. Only the treatment group enrolled prospectively is included in our analysis.
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and males comprised between 34% and 94% of the study populations. (Figure 2b ) 17, 23, [30] [31] [32] [33] [34] 37, 40, 44, 47, 48 ; and 1.92 (95% CI ¼ 1.41 to 2.69) across 7 studies at 36-months follow-up (Figure 2c ). [18] [19] [20] 23, 39, 44, 46 Neck Disability Index and Nurick Grade. Seven studies assessed change in NDI scores (follow-up duration ranged from 12 to 99.7 months) 18, 20, 22, 35, 44, 47, 48 and 5 studies evaluated change in Nurick grade (follow-up duration ranged from 12 to 24 months). 22, 29, 38, 42, 48 The risk of bias was low or moderately low in 4 studies reporting NDI 18, 22, 44, 48 and in 2 studies reporting Nurick grade. 22, 48 The remaining studies were classified as high or moderately high risk of bias because of undefined or low follow-up rates. 20, 29, 35, 38, 42, 47 A strong effect for improvement was observed at each time point (P < .001) for both NDI and Nurick scores. For up to 12-months follow-up, the pooled MD for NDI was 18.02 (95% CI ¼ 11.02 to 25.02) across 5 studies ( Figure  3a ) 20, 22, 35, 44, 48 and 1.42 (95% CI ¼ 1.11 to 1.74) for Nurick across 2 studies (Figure 4a) . 22, 48 In the medium term (13-36 months), the pooled MD for NDI was 19.71 (14.01 to 25.42) across 5 studies (Figure 3b (Figure 4b) . 29, 38, 42, 48 In the long term (over 36 months), the pooled MD for NDI was 23.21 (95% CI ¼ 11.84 to 34.58) across 2 studies (Figure 3c ). 18, 20 Visual Analog Scale for Pain. Five studies reported change in VAS scores with follow-up duration ranging from 6 to 72 months. 20, 30, 34, 44, 47 The risk of bias was low or moderately low in 3 studies, 30 ,34,44 and moderately high in 2 studies because of undefined or low follow-up rates 20, 47 and/or concerns regarding selection bias. 47 A strong effect was seen for improvement in pain at each time point (P < .001): the pooled MD was 32.74 (95% CI ¼ 18.39 to 47.10) across 4 studies at 12-months follow-up (Figure 5a ) 20 (Figure 5b) . 20, 30, 34, 35, 44, 47 The MD from one study was 40.00 (95% CI ¼ 37.01 to 42.99) at greater than 36-months follow-up (Figure 5c ). 20 
Effect of Preoperative Duration of Symptoms and Myelopathy Severity on Surgical Outcomes
Four studies stratified their sample based on preoperative duration of symptoms (<6, 6-12, >12 months 19 ; <12 or >12 months 26, 39 ; or <12, 12-24, and >24 months 38 ) ( Table 3 ). Patients in these subgroups exhibited similar functional improvements as assessed by JOA or mJOA scores. 19, 26, 39 A fifth study by Tetreault et al evaluated whether duration of symptoms is a significant predictor of a postoperative mJOA score 16. 41 Based on their results, the odds of achieving a mJOA 16 decreased by 22% when a patient moved from a shorter to a longer duration of symptoms group (3; >3, 6; >6, 12; >12, 24; >24 months) (adjusted odds ratio: 0.78; 95% CI ¼ 0.61 to 0.997; P ¼ .048).
Two studies compared postoperative outcome in cohorts of varying preoperative myelopathy severities (Table 4) . 20, 22 Two other studies examined the association between baseline severity scores and surgical outcomes. 37, 41 With respect to change in mJOA, Fehlings et al 22 reported improvements across all levels of impairment; patients with severe myelopathy (mJOA < 12), however, demonstrated the greatest functional change (4.91, 95% CI ¼ 4.34 to 5.49), whereas those with mild disease (mJOA 15) achieved the least amount of improvement (1.29, 95% CI ¼ 0.70 to 1.87; Table 4 ). Conversely, Chibbaro et al 20 reported that a similar percentage of patients with either moderate (mJOA ¼ 10-13) or severe (mJOA ¼ 5-9) myelopathy exhibited improvement on the mJOA scale at long-term followup (96 months). In a study by Tetreault et al, 41 the odds of achieving a mJOA 16 at 1-year following surgery was 1.22 times greater for every 1-point increase in preoperative mJOA score. A complementary result was observed in a study by Setzer et al, 37 who reported that patients with more severe preoperative impairment were less likely to exhibit a postoperative improvement of 2 or more points on the mJOA scale at 18-months follow-up (odds ratio ¼ 0.72; 95% CI ¼ 0.66 to 0.92). 37 
Complications
Pooled estimates of complications across included studies are presented in Table 5 in order of decreasing frequency. The cumulative incidence of complications is low (14.1%; 95% CI ¼ 10.1% to 18.2%). Mortality was reported in 0.3% of patients (95% CI ¼ 0.0% to 0.5%). Neurological complications included worsening of myelopathy (1.3%; 95% CI ¼ 0.5% to 2.1%), laryngeal nerve injury/dysphagia (2.2%; 95% CI ¼ 1.4% to 3.0%), and C5 radiculopathy or palsy (1.9%; 95% CI ¼ 1.4% to 2.4%). Infection was infrequent and reported in 1.5% of patients (95% CI ¼ 1.0% to 2.1%). Instrumentation or graft complication occurred in 2.0% of cases (95% CI ¼ 1.3% to 2.7%).
Evidence Summary
The evidence summary is presented in Table 6 .
Effect of Surgery on Functional Impairment, Disability and Pain.
There is moderate strength of evidence that surgical intervention for DCM results in significant improvements in function at short-, medium-, and long-term follow-up as assessed by JOA or mJOA scores. Clinically meaningful improvements in both the NDI and Nurick scores were also observed following surgery. However, the strength of evidence for these findings was rated as very low for NDI and low for Nurick score. Finally, based on moderate evidence, surgical intervention results in significant improvements in pain scores at 6-to 12-months follow-up. 
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Effect of Preoperative Duration of Symptoms and Myelopathy
Severity on Surgical Outcomes. There is very low strength of evidence that preoperative duration of symptoms is not associated with surgical outcomes, evaluated by change in JOA or mJOA scores between patients with a duration of symptoms greater than or less than 12 months. There is low strength of evidence that the odds of achieving a postoperative mJOA 16 decrease as duration of symptoms increases. There is moderate strength of evidence that improvements on the mJOA are less for patients with mild myelopathy than those with moderate or severe disease. There is low strength of evidence that the odds of achieving a postoperative mJOA 16 decrease as preoperative myelopathy severity increases. Based on very low strength of evidence, improvement in NDI and Nurick scores do not depend on preoperative disease severity.
Complications. Surgical complications occur infrequently in patients treated surgically for DCM. C5 radiculopathy or palsy and surgical site infection were reported in fewer than 2% of patients. The strength of evidence for these estimates is low. The cumulative incidence of reoperation, dural tears, worsening of myelopathy, and death was less than 1.5% and was 2% for instrumentation failure. The strength of evidence to support these estimates is very low.
Discussion
The management of DCM remains controversial with limited evidence available to the clinician and patient to make informed decisions. The only randomized controlled trial 5, 6 concluded that there is no difference in mJOA scores between patients with "milder" DCM (mJOA 12) that receive operative versus nonoperative care. This is in contrast to results reported in other observational studies, 7, 8 which suggest that surgery leads to superior functional recovery. These conflicting results highlight the importance of patient selection and identifying ideal surgical candidates. Further controversy arises because there are a variety of surgical techniques available to the surgeon to accomplish the objectives of spinal cord decompression, spinal column stabilization, and, if necessary, spinal realignment. Based on a study by Fehlings et al, patients treated anteriorly or posteriorly exhibit similar improvements 22 ; however, selection criteria between approaches remain controversial and is the topic of a current randomized controlled trial of ventral versus dorsal surgery. 49 There is a lack of evidence on the comparative effectiveness of surgery and nonoperative treatment in patients with DCM. As a result, this systematic review aims to summarize data from prospective studies that report changes in outcomes and rates of complications associated with surgical intervention.
The first objective of this review was to determine the change in functional impairment, disability, and pain following surgical management. Based on our conclusions, there is moderate evidence to suggest that surgery results in significant gains in mJOA or JOA scores at short-, medium-, and longterm follow-up. These reported improvements exceed the minimum clinically important difference for this metric, 50, 51 suggesting that patients undergoing surgery are expected to exhibit functional gains in addition to disease stabilization. Furthermore, based on low evidence, surgery also results in significant improvements in Nurick scores at short-and medium-term follow-up. The mJOA has been adopted as the standard for evaluating functional impairment in patients with DCM; this scale is responsive to change, especially in patients with moderate and severe myelopathy. 52 Reported improvements on the Nurick Grade were less than those observed on the mJOA; however, this is likely because this scale only has 6 categories and because it is inherently less sensitive.
The second objective of this review was to evaluate whether duration of symptoms or preoperative myelopathy severity were associated with surgical outcomes. Based on our findings, operative management results in significant functional improvements in patients with both a "short" and "long" duration of symptoms and in patients with mild, moderate, and severe disease. The clinical prediction rule proposed by Tetreault et al, 41 however, suggested that the likelihood of achieving a postoperative mJOA 16 decreases with a longer duration of symptoms and a lower baseline severity score. The authors of this study acknowledged that patients with severe myelopathy are, in part, less likely to attain a postoperative mJOA 16 as this would require a 5-point improvement; to address this limitation, a second model was developed to predict a postoperative mJOA 12 and also included baseline severity score as a relevant factor. 48 Future studies are required to validate these associations and should use outcome measures that are better suited to assess patients with mild myelopathy. In a recent review, Kalsi-Ryan et al 53 suggested that ancillary measures be used in combination with the mJOA or JOA scale to assess impairment in patients with DCM; these include tools that focus on upper extremity function (Graded Redefined Assessment of Strength Sensibility and Prehension and grip dynamometer), gait (GAITRite analysis and 30-meter walk test), and balance (Berg Balance Score).
The third objective of this review was to evaluate the incidence of surgical complications. The quality of evidence for our conclusions was low to very low, due to risk of bias and imprecision. The imprecision of our estimates likely results from the variability of definitions across studies; this highlights a major knowledge gap and a need to develop a classification system for surgical complications. Nevertheless, reported cumulative incidences were low for perioperative mortality (0.3%), recurrent laryngeal nerve injury or dysphagia (2.2%), and C5 radiculopathy or palsy (1.9%). Nationwide estimates of perioperative morbidity have previously been presented by Shamji et al 54, 55 ; their results indicated that, among 8548 patients with diffuse cervical spondylosis, rates of mortality were 0.33% and 0.69% in patients approached anteriorly and posteriorly, respectively. Dysphagia was reported in 3.63% of patients approached anteriorly and 1.87% of patients approached posteriorly. Posterior surgery was associated with a more frequent need for transfusion (1.38% anteriorly, 7.20% posteriorly) and a higher rate of clinically significant hematoma (0.80% anteriorly, 2.12% posteriorly).
The cost-effectiveness of surgery must also be considered when developing treatment protocols. Two studies were identified that evaluated the cost-utility of surgery in Canadian patients enrolled in the AOSpine North America and/or International studies. The first study (based on the North America study) estimated the cost of surgery to be $21 066.44, with an incremental cost-utility ratio (ICUR) of $32 916 per quality adjusted life year (QALY). 56 A second study by Witiw et al (based on the North America and International studies) conducted a more rigorous cost-utility analysis using a 2-arm, Markov State Transition model where values for subjects undergoing surgery were compared with estimated counterfactual outcomes of initial conservative management. 57 In a primary model, the lifetime ICUR was determined to be $11 496/ QALY gained for surgical intervention, an estimate considered very cost-effective according to criteria defined by the World Health Organization. Further testing using a Monte Carlo probabilistic sensitivity analysis revealed that 97.9% of estimates fell within the WHO threshold, suggesting robustness to variability in the parameter estimates. To supplement this testing, a highly conservative assumption that individuals undergoing initial nonoperative management would not experience any neurologic decline over their lifetime was added to the model. In this scenario, the ICUR was calculated as $20 548/QALY gained with 94.7% of estimates falling within the WHO threshold; this finding further supports the cost-effectiveness of surgical intervention. Unfortunately, these analyses only explored the cost-effectiveness of surgery in Canada and did not stratify their sample based on preoperative myelopathy severity.
Limitations
A substantial limitation of this systematic review is that the impact of surgical approach on recovery was not studied. Surgical interventions vary in both approach (anterior or posterior) and objectives (decompression, stabilization, realignment); as a result, data may be too heterogeneous to conduct a meta-analysis. Among anterior surgical approaches, a previous systematic review 58 demonstrated heterogeneous neurological, pain, and alignment outcomes among multiple discectomy, corpectomy, and hybrid procedures. Among posterior surgical approaches, a previous systematic review by Yoon et al 59 reported that both laminoplasty and laminectomy and fusion procedures result in functional improvement. Unfortunately, the comparative effectiveness and safety of these and other approaches have not been rigorously addressed. (continued) 
Low
Pooled cumulative incidence of C5 radiculopathy or palsy is 1.9% (95% CI 1.4, 2.4).
(continued)
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Conclusions
Based on our conclusions, in patients with DCM, surgery prevents further disease progression and also results in significant gains in functional impairment, disability, and pain. A shorter duration of symptoms and less severe myelopathy preoperatively are both important predictors of achieving a postoperative mJOA 16. Finally, surgery for DCM is a relatively safe treatment option, with a cumulative incidence of complications estimated at 14.1%.
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